Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 11/20 | 0.60 |
| ▸ | NT5E | P21589 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18521312 | 1.00 | RNASEL (0.60) | RNASELNT5E | |
| SCHEMBL18521011 | 1.00 | RNASEL (0.60) | RNASELNT5E | |
| SCHEMBL18511003 | 1.00 | RNASEL (0.60) | RNASELNT5E | |
| SCHEMBL18521632 | 1.00 | RNASEL (0.60) | RNASELNT5E | |
| SCHEMBL18521080 | 0.96 | RNASEL (0.66) | RNASEL | |
| SCHEMBL22326713 | 0.96 | RNASEL (0.66) | RNASEL | |
| SCHEMBL18521005 | 0.96 | RNASEL (0.66) | RNASEL | |
| SCHEMBL18521345 | 0.96 | RNASEL (0.66) | RNASEL | |
| SCHEMBL18521119 | 0.96 | RNASEL (0.66) | RNASEL | |
| SCHEMBL18510885 | 0.96 | RNASEL (0.66) | RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | RNASEL 574/4885NT5E 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.